Affiliation:
1. Department of Pharmaceutics, NSHM Knowledge Campus, Kolkata- Group of Institutions, Kolkata, West Bengal, India
2. Department of Pharmacology, NSHM Knowledge Campus, Kolkata- Group of Institutions, Kolkata, West Bengal, India
Abstract
In the past, few decades cancer has become a worldwide problem to mankind. Lung cancer is the most life-threatening among all cancer types. Non-small cell lung cancer (NSCLC) is the main reason for approximately 80% to 90% of deaths. Lack of early detection and incompetent conventional therapies is the leading cause for poor prognosis and overall survival rate of lung cancer patients. Immense progress in the field of nanotechnology and nanomedicine has given inspiration to the development of an alternative strategy in the treatment of lung cancer. The unique physicochemical properties of the nanoparticles likeability to cross the different biological barriers, effectiveness in delivering hydrophobic drugs which are difficult to incorporate in the body, and targeting in the particular disease sites have given rise to enormous advantages for nanoparticulate systems for the early diagnosis and active delivery of drugs for a better treatment for lung cancer. Recently, many formulations of nanocarriers like lipid-based, polymeric and branched polymeric, metal-based, magnetic, and mesoporous silica are being used in this treatment. Innovative strategies have been employed to utilize the multicomponent, three-dimensional structure of nanoparticles and modify it and construct a new structure moiety that has multifunctional capabilities. Developing such designs permits simultaneous drug delivery of chemotherapeutics as well as anticancer gene therapies to site-specific targets. In lung cancer, nanoparticle-based therapeutics is now breaking the ground in the diagnosis, imaging, screening, and treatment of primary and metastatic tumors. This review emphasizes the pathogenesis of lung cancer and its treatment by nanotechnology.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A Comparative Study of Montelukast and Salbutamol in Bronchial Asthma;International Journal of Scientific Research in Science and Technology;2022-09-01